Amarillo Biosciences, Inc. (ABI) (OTC BB: AMAR) today announced that Lorenz O. Lutherer, M.D., Ph.D. and Cynthia Jumper, MD, Professors of Internal Medicine at Texas Tech University Health Sciences Center, presented data in Atlanta at the Southern Regional Meeting of the Society for Clinical Investigations on low-dose orally-administered interferon alpha (IFNa) as a treatment for idiopathic pulmonary fibrosis (IPF). The study, which commenced in 2001 and is ongoing, was funded by a grant from the State of Texas Higher Education Coordinating Board, Applied Technology Program. The IFNa lozenges are being supplied by ABI.
